Consiglio Nazionale delle Ricerche

Tipo di prodottoArticolo in rivista
TitoloEffects of pioglitazone on insulin sensitivity and serum lipids in obese cats
Anno di pubblicazione2014
Formato
  • Elettronico
  • Cartaceo
Autore/iClark, M. and Thomaseth, K. and Dirikolu, L. and Ferguson, D.C. and Hoenig, M.
Affiliazioni autoriDepartment of Comparative Biosciences, University of Illinois, College of Veterinary Medicine, Urbana, IL, United States; Institute of Biomedical Engineering - ISIB, CNR - National Research Council of Italy, Padova, Italy; Department of Veterinary Clinical Medicine, University of Illinois, College of Veterinary Medicine, Urbana, IL, United States
Autori CNR e affiliazioni
  • KARL THOMASETH
Lingua/e
  • inglese
AbstractBackground: Pioglitazone is a thiazolidinedione (TZD) insulin sensitizer approved for use in human type 2 diabetes mellitus. Therapeutic options for diabetes in cats are limited. Objective: To evaluate the effects of pioglitazone in obese cats, which are predisposed to insulin resistance, to assess its potential for future use in feline diabetes mellitus. Animals: A total of 12 obese purpose-bred research cats (6 neutered males and 6 spayed females, 5-7 years of age, weighing 5.4-9.8 kg). Methods: Randomized, placebo-controlled 3-way crossover study. Oral placebo or pioglitazone (Actos(TM); 1 or 3 mg/kg) was administered daily for 7-week periods, with IV glucose tolerance testing before and after each period. Results: Three mg/kg pioglitazone significantly improved insulin sensitivity (geometric mean [95% CI] 0.90 [0.64-1.28] to 2.03 [1.49-2.78] min -1pmol-1L; P = .0014 versus change with placebo), reduced insulin area under the curve during IVGTT (geometric mean [range] 27 [9-64] to 18 [6-54] minbullet operatornmol/L; P = .0031 versus change with placebo), and lowered serum triglyceride (geometric mean [range] 71 [29-271] to 48 [27-75] mg/dL; P = .047 versus change with placebo) and cholesterol (geometric mean [range] 187 [133-294] to 162 [107-249] mg/dL; P = .0042 versus change with placebo) concentrations in the obese cats. No adverse effects attributable to pioglitazone were evident in the otherwise healthy obese cats at this dosage and duration. Conclusions and Clinical Importance: Results of this study support a positive effect of pioglitazone on insulin sensitivity and lipid metabolism in obese cats, and suggest that further evaluation of the drug in cats with diabetes mellitus or other metabolic disorders might be warranted.
Lingua abstractinglese
Altro abstract-
Lingua altro abstract-
Pagine da166
Pagine a174
Pagine totali-
RivistaJournal of veterinary internal medicine
Attiva dal 1987
Editore: Wiley Periodicals - Malden, MA
Paese di pubblicazione: Stati Uniti d'America
Lingua: inglese
ISSN: 0891-6640
Titolo chiave: Journal of veterinary internal medicine
Titolo proprio: Journal of veterinary internal medicine.
Titolo abbreviato: J. vet. intern. med.
Numero volume della rivista28
Fascicolo della rivista1
DOI10.1111/jvim.12255
Verificato da refereeSì: Internazionale
Stato della pubblicazione-
Indicizzazione (in banche dati controllate)
  • Scopus (Codice:2-s2.0-84892481710)
Parole chiave-
Link (URL, URI)http://www.scopus.com/inward/record.url?eid=2-s2.0-84892481710&partnerID=40&md5=1809c40350dab98d0c12fcfda50462e6
Titolo parallelo-
Data di accettazione-
Note/Altre informazioni-
Strutture CNR
  • IEIIT — Istituto di elettronica e di ingegneria dell'informazione e delle telecomunicazioni
Moduli CNR-
Progetti Europei-
Allegati
Articolo pubblicato (documento privato )
Tipo documento: application/pdf